Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia.

Autor:	Fink HA; Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota (H.A.F., J.R.M., L.S.H., T.J.W.)., Linskens EJ; Minneapolis VA Health Care System, Minneapolis, Minnesota (E.J.L., N.L.G.)., Silverman PC; University of Iowa Carver College of Medicine, Iowa City, Iowa (P.C.S.)., McCarten JR; Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota (H.A.F., J.R.M., L.S.H., T.J.W.)., Hemmy LS; Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota (H.A.F., J.R.M., L.S.H., T.J.W.)., Ouellette JM; University of Minnesota, Minneapolis, Minnesota (J.M.O., M.B.)., Greer NL; Minneapolis VA Health Care System, Minneapolis, Minnesota (E.J.L., N.L.G.)., Wilt TJ; Minneapolis VA Health Care System and University of Minnesota, Minneapolis, Minnesota (H.A.F., J.R.M., L.S.H., T.J.W.)., Butler M; University of Minnesota, Minneapolis, Minnesota (J.M.O., M.B.).
Jazyk:	angličtina
Zdroj:	Annals of internal medicine [Ann Intern Med] 2020 May 19; Vol. 172 (10), pp. 669-677. Date of Electronic Publication: 2020 Apr 28.
DOI:	10.7326/M19-3888
Abstrakt:	Background: Biomarker accuracy for Alzheimer disease (AD) is uncertain. Purpose: To summarize evidence on biomarker accuracy for classifying AD in older adults with dementia. Data Sources: Electronic bibliographic databases (searched from January 2012 to November 2019 for brain imaging and cerebrospinal fluid [CSF] tests and from inception to November 2019 for blood tests), ClinicalTrials.gov (to November 2019), and systematic review bibliographies. Study Selection: English-language studies evaluating the accuracy of brain imaging, CSF testing, or blood tests for distinguishing neuropathologically defined AD from non-AD among older adults with dementia. Studies with low or medium risk of bias were analyzed. Data Extraction: Two reviewers rated risk of bias. One extracted data; the other verified accuracy. Data Synthesis: Fifteen brain imaging studies and 9 CSF studies met analysis criteria. Median sensitivity and specificity, respectively, were 0.91 and 0.92 for amyloid positron emission tomography (PET), 0.89 and 0.74 for 18 F-labeled fluorodeoxyglucose ( 18 F-FDG) PET, 0.64 and 0.83 for single-photon emission computed tomography, and 0.91 and 0.89 for medial temporal lobe atrophy on magnetic resonance imaging (MRI). Individual CSF biomarkers and ratios had moderate sensitivity (range, 0.62 to 0.83) and specificity (range, 0.53 to 0.69); in the few direct comparisons, β-amyloid 42 (Aβ42)/phosphorylated tau (p-tau) ratio, total tau (t-tau)/Aβ42 ratio, and p-tau appeared more accurate than Aβ42 and t-tau alone. Single studies suggested that amyloid PET, 18 F-FDG PET, and CSF test combinations may add accuracy to clinical evaluation. Limitations: Studies were small, biomarker cut points and neuropathologic AD were inconsistently defined, and methods with uncertain applicability to typical clinical settings were used. Few studies directly compared biomarkers, assessed test combinations, evaluated whether biomarkers improved classification accuracy when added to clinical evaluation, or reported harms. Conclusion: In methodologically heterogeneous studies of uncertain applicability to typical clinical settings, amyloid PET, 18 F-FDG PET, and MRI were highly sensitive for neuropathologic AD. Amyloid PET, 18 F-FDG PET, and CSF test combinations may add accuracy to clinical evaluation. Primary Funding Source: Agency for Healthcare Research and Quality. (PROSPERO: CRD42018117897).
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu